Literature DB >> 12732848

Cytochrome P4502C9 activity in end-stage renal disease.

Albert W Dreisbach, Shanker Japa, Aster B Gebrekal, Sarah E Mowry, Juan J L Lertora, Burde L Kamath, Allan E Rettie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12732848     DOI： 10.1016/s0009-9236(03)00015-8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  35 in total

1.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

Review 2.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

Review 3.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

5.  Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease?

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 6.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 7.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

8.  Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease.

Authors:  Felix Yang; Jessica A Hellyer; Claire Than; Aditya J Ullal; Daniel W Kaiser; Paul A Heidenreich; Donald D Hoang; Wolfgang C Winkelmayer; Susan Schmitt; Susan M Frayne; Ciaran S Phibbs; Mintu P Turakhia
Journal:  Heart       Date:  2016-11-15       Impact factor: 5.994

9.  Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism.

Authors:  Xiaowei Gong; Haiyan Wang; Yadong Yuan
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

10.  Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine.

Authors:  Osama Y Alshogran; Andrew J Ocque; François A Leblond; Vincent Pichette; Thomas D Nolin
Journal:  J Chromatogr Sci       Date:  2015-12-11       Impact factor: 1.618
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.